Arrowhead Pharmaceuticals (ARWR) is back in focus as investors react to progress in its RNA interference drug pipeline, including two therapies in Phase 3 trials and multiple partnerships with large pharmaceutical partners.

The recent excitement around Arrowhead’s RNAi pipeline and partnerships comes after a choppy few weeks for the stock, with a 1 month share price return of an 8.74% decline but a 90 day share price return of 12.48%. Over a longer window, momentum looks stronger, with a 1 year total shareholder return of 234.58% and a 3 year total shareholder return of 95.58%, even though the 5 year total shareholder return of an 8.30% decline shows earlier investors have not had a smooth ride.

If this biotech story has your attention, it could be a good moment to scan other potential RNA and genomics peers through our screener of 27 healthcare AI stocks and see what stands out next.

With Arrowhead trading at US$63.27, some investors will point to its intrinsic value estimate and analyst targets as signs of a discount, while others may wonder if the recent gains mean the market is already pricing in future growth.

Most Popular Narrative: 1.3% Undervalued

Arrowhead’s latest fair value narrative points to a price of $64.08, only slightly above the last close at $63.27, which keeps attention firmly on the assumptions behind that number.

Progress in RNAi delivery technology (TRiM platform), pipeline breadth in both prevalent and rare/orphan indications, and first-mover potential in CNS and adipose tissue RNAi expand Arrowhead's competitive edge as advancements in genomics and precision medicine increase the feasibility and personalization of RNAi therapies supporting stronger projected net margins and long-term earnings growth if adoption broadens.

Curious what kind of revenue path and profit margin shift would need to sit behind that fair value, and how a high implied future earnings multiple fits into the story? The most followed narrative lays out a detailed earnings bridge, plus the discount rate used to pull those future cash flows back to today, but keeps one core assumption that could make or break the case.

Result: Fair Value of $64.08 (UNDERVALUED)

However, the story could look different if partnership payments become less predictable, or if late stage trial results and regulatory decisions do not land as expected.

Another Angle on Valuation

That fair value of $64.08 contrasts sharply with how the market is pricing Arrowhead today on earnings. The current P/E sits at 43.8x, versus 21.7x for the US Biotechs industry and a fair ratio of 20.2x. This suggests a rich premium that could matter if sentiment cools.

Next Steps

Does this mix of optimism and caution fit with how you see Arrowhead right now, or not quite? If you want to move quickly and build your own view using the same checklist investors are watching, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Arrowhead has sharpened your interest, do not stop here. Use the screener to quickly spot other opportunities that fit the kind of portfolio you want to build.

• Focus on value first by checking companies that screen as potential bargains through our list of 46 high quality undervalued stocks that already clear key quality checks.
• Prioritize staying power by reviewing businesses on the solid balance sheet and fundamentals stocks screener (39 results) that pair financial resilience with fundamentals many investors watch closely.
• Get ahead of the crowd by scanning the screener containing 24 high quality undiscovered gems where strong underlying metrics have not yet attracted as much attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.